Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis

Figure 2 Kaplan-Meier analysis of cumulative resistance (A) and survival (B) rate in patients with hepatitis B virus-related decompensated cirrhosis on de novo lamivudine and adefovir dipivoxil combination therapy and lamivudine monotherapy. A: No resistance occurred in de novo combination group up to 144 wk. The cumulative resistance rate in lamivudine monotherapy group at weeks 48, 96 and 144 was 20%, 36.8% and 56.9%, respectively; B: The cumulative survival rate in de novo combination group was 91.4%, 81.6% and 75.7% at weeks 48, 96 and 144, respectively. The cumulative survival rate in lamivudine monotherapy group was 90.6%, 81.6% and 72.8%, respectively.